Home / People / Maria Letizia Patania
Portrait ofMaria Letizia Patania

Maria Letizia Patania

Partner

CMS Adonnino Ascoli & Cavasola Scamoni
Via A. Depretis 86
00184 Rome
Italy
Languages Italian, English

Maria Letizia Patania began her collaboration with the Firm in 2004.

Her work in the Rome office focuses on commercial and pharmaceutical law and commercial litigation, both in arbitration proceedings and before the judicial authorities. Throughout her career she has also developed significant experience with regards to the legal liability of legal persons.

As for the latter, Maria Letizia has assisted numerous companies in the drafting of ex L. 231/01 models and in their regular updating.
Her clients include important companies operating in the healthcare sector, in the field of fuel storage and distribution, energy services and infrastructure services. Maria Letizia is currently chairman of the Compliance Program Supervisory Boards of several important Italian energy companies.

more less

Memberships & Roles

  • Rome Bar Association
more less

Education

  • 2006 – Admitted to the Rome Bar Association
  • 2004 – Postgraduate diploma in commercial law
  • 2003 – University of Rome “LUISS Guido Carli”, Law Degree
more less

Feed

15/04/2024
Green/sus­tain­ab­il­ity claims and advertising and consumer greenwashing
In the era of increased environmental awareness, the spotlight on green claims has never been more intense. As consumers are concerned about global heating and ecological sustainability, they are scrutinizing products like never before, seeking eco-friendly options that align with their values. In response, businesses have responded to this concern and consumers’ purchase interest, with brand-owners increasingly highlighting the benign or even beneficial effects their products and services have on the environment fostering a surge in green marketing initiatives. Yet, amidst this push for sustainability, the risk of being accused of greenwashing is omnipresent. As environmental characteristics of products and services are highly technical and the understanding of the various concepts involved is continuously changing, en­vir­on­ment­al/sus­tain­ab­il­ity claims raise a significant risk of confusing and misleading consumers. Many companies have fallen foul of advertising standards in this area recently. Given the high sensitivity of environmental claims and the reputational damage that can result from allegations of greenwashing, it is particularly important to make sure environmental claims are compliant. By ensuring truthful, accurate and unambiguous information is always given to the consumers, companies can avoid the risks and build a reputation for authenticity in their sustainability advertising and communications. CMS guides companies through the maze of regulations and case law and advise on the steps a company can take to ensure their advertising is not only compliant but also authentic and impactful. The priority questions we address are: Which green claims are likely to raise litigation or regulatory enforcement risks?What can businesses do to mitigate these risks?What are the likely claims/en­force­ment that could arise?Who is likely to make a claim?What are the risks in the event of a violation or a complaint? What future regulatory measures are expected and what companies have to do now to be prepared? We offer various solutions to help you be compliant and avoid accusations of greenwashing: Sustainability claim checks including regulatory risk matrix as well as litigation: evaluating the planned claims and mapping their risk as well as developing compliant marketing strategies and claims custom-tailored to your business's unique pro­file;Sus­tain­ab­il­ity-re­lated litigation: providing comprehensive support in legal disputes in the area of advertising with environmental claims;Training sessions: to empower your legal, compliance and sustainability as well as advertising teams with in-depth knowledge of sustainability risks and mitigation strategies; andBoard packs: to equip your directors/board members with actionable insights into greenwashing risks, ensuring they steer the company toward sustainable strategies with confidence and integrity.  For an initial conversation on how we can support you on greenwashing risk, please reach out to the lawyers listed on this page or to your usual CMS contact.
27/03/2024
Cannabis law and legislation in Italy
Medical use Growing, selling and importing medical cannabis is allowed on the condition that the authorisation of the Ministry of Health is obtained. Cultivation, sale and import are currently mainly...
14/02/2024
Recognition and enforcement of foreign judgments in Italy
1. Is there an exequatur procedure? Yes. Recognition of a foreign judgment takes place automatically as long as the requirements are met and no grounds for refusal are invoked. Execution can be sought...
18/12/2023
Digital health apps and telemedicine in Italy
Digital Health Apps/Software 1. How is the software within digital health apps classified in your jurisdiction, and what regulation(s) apply? 1.1 Is it considered a “medical device” or a “product”...
Comparable
28/10/2022
Italian reform on arbitration: new rules on provisional measures and expedited...
By Legislative Decree No. 149 of 10 October 2022 (the "Decree 149/2022"), the Italian Government has introduced significant amendments to the Italian rules governing the arbitration proceedings. The amendments...
27/10/2022
Legislative Decree No. 149 of 10 October 2022 - the new rules on Italian...
By Legislative Decree No. 149 of 10 October 2022 (the "Decree 149/2022"), the Italian Government has made significant amendments to the provisions of the Italian Code of Civil Procedure ("CCP") governing...
15/09/2022
Pharmaceutical advertising regulation and medical device advertising in...
1. Which laws are applicable regarding advertising of medicines and medical devices? Advertising of medicines is regulated in a specific section of Legislative Decree no. 219/2006 (“Code of Medicines”)...
15/06/2022
The new Italian Sunshine Act
The Social Affairs Commission of the Italian Chamber of Deputies recently approved the final version of the so-called Sunshine Act, bearing “Provisions on the transparency of relations between manufacturing...
07/06/2022
Adverse effects of drugs and vaccines in Italy
1. Drug adverse effects: kinds of responsibility 1.1 Which are the main kinds of responsibility (contractual, in tort, criminal) of the following subjects with respect to adverse drugs reactions? A...
Comparable
10/12/2021
Law 10 November 2021, n. 175: in the Official Gazette the new provisions...
On November 27, 2021, Law No. 175/2021, setting forth "Provisions for the treatment of rare diseases and for the support of research and production of orphan drugs." was published in the Official Gazette...
01/12/2021
Law 10 November 2021, n. 175: the new provisions for the treatment of rare...
On November 27, 2021, Law No. 175/2021, setting forth "Provisions for the treatment of rare diseases and for the support of research and production of orphan drugs." was published in the Official Gazette...
23/03/2020
Covid-19 in Italy: simplified procedures for pharmaceuticals and clinical...
In the context of the COVID-19 emergency, both the Council of Ministers and the Italian Regulator (AIFA - Agenzia Italiana del Farmaco) have issued some measures mainly aimed at streamlining the authorization...